| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | — | -20.3% |
| R&D Expense | $24.7M | — | -15.2% |
| SG&A Expense | $9.6M | — | -30.3% |
| Operating Income | -$33.0M | — | +20.1% |
| Net Income | -$31.2M | — | +17.0% |
| EPS (Basic) | -$0.26 | — | +18.8% |
| EPS (Diluted) | -$0.26 | — | +18.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $39.6M | -15.1% | -11.9% |
| Short-term Investments | $135.3M | -13.9% | -30.8% |
| Accounts Receivable | $704K | -23.1% | -70.7% |
| Current Assets | $179.5M | -14.0% | -27.7% |
| Total Assets | $284.9M | -10.7% | -28.5% |
| Current Liabilities | $30.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$30.8M | — | +8.8% |
| Capital Expenditures | $239K | — | -80.0% |
| Investing Cash Flow | $23.6M | — | -44.7% |
| Free Cash Flow | -$31.1M | — | +11.3% |
| +9.0% |
| Stockholders' Equity | $179.7M | -13.3% | -37.7% |